The forecast for the import of insulin to Singapore shows a steady annual increase from 2024 to 2028. With the value standing at 6.2484 million USD in 2024, the projections indicate it will rise to 7.165 million USD by 2028. Given that the data points for 2023 are absent, it is clear from the forecast data that there is an expected consistent growth. Year-on-year variation highlights a stable growth pattern with the percentage increase per year demonstrating a typical upward trend. Over the five-year period, the Compound Annual Growth Rate (CAGR) underscores a moderate, sustainable increase in insulin imports.
Future trends to watch for include advancements in diabetes treatment, potential price variations due to global market fluctuations, and Singapore's healthcare policies impacting import volumes. Monitoring these factors will be essential for anticipating any substantial shifts in demand or supply dynamics.
